The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Aug. 21, 2:00 PM

Slide #5. NeoGenomics, Inc. Secondary Offering

Company: NeoGenomics, Inc. (NASDAQ:NEO)
Date announced: 8/14/2014
Shares Offered: 7,000,000
Date of Pricing: 8/15/2014
Price Per Share: $4.60
Secondary Offering Details: NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by NeoGenomics.- updated 8/15 - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of cancer-focused genetic testing services, today announced that it has priced an underwritten public offering of 7.0 million shares of common stock at a price to the public of $4.60 per share. The transaction is expected to close on August 20, 2014 and will result in gross proceeds to NeoGenomics of $32.2 million. The net proceeds to the Company, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $30.0 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes, including potential acquisitions and the repayment of debt. NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover over-allotments, if any.

NeoGenomics operates a network of cancer-focused testing laboratories that provides genetic and molecular testing services, including: cytogenetics testing, which studies normal and abnormal chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization testing, which detects and locates the presence or absence of certain deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which measures the characteristics of cell populations; immunohistochemistry testing, which identifies cell proteins in a tissue section; and molecular testing, which analyzes the DNA and ribonucleic acid, and the structure and function of genes at a molecular level.
Open the NEO Page at The Online Investor »

Company Name:  NeoGenomics Inc
Sector:  Diagnostics
Number of ETFs Holding NEO:  8
Total Market Value Held by ETFs:  $52.48M
Total Market Capitalization:  $263.00M
% of Market Cap. Held by ETFs:  19.96%

Open the NEO Page at The Online Investor (in a new window) »

August 21, 2014    2:00 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
86th percentile
(ranked higher than approx. 86% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.